Compositions and methods for treating HCV
View Patent ↗This disclosure is directed to pharmaceutical compositions that comprise two or more therapeutic agents that, inter alia, are useful for inhibiting hepatitis C virus (HCV) and methods for inhibiting HCV by co-administering two or more anti-HCV therapeutic agents.
1. A method for treating a subject infected with hepatitis C virus (HCV) genotype 1, said method comprising administering to said subject an amount of therapeutic agent A and an amount of therapeutic agent B, wherein therapeutic agent A is compound A or a salt thereof:
wherein therapeutic agent B is compound B or a salt thereof:
wherein the molar ratio of therapeutic agent A to therapeutic agent B is about 1:20 to about 1:2000, and wherein therapeutic agent A and therapeutic agent B are administered to the subject from the same pharmaceutical composition.
2. The method of claim 1 , wherein the subject is a human.
3. The method of claim 1 , wherein the total daily dosage amount of therapeutic agent A administered to the subject is about 25 mg.
4. The method of claim 1 , wherein therapeutic agent B is a sodium salt of compound B.
5. The method of claim 1 , wherein the method further comprises administering one or more additional therapeutic agents selected from the group consisting of interferon, ribavirin, taribavirin, and HCV inhibitor.
6. The method of claim 5 , wherein the additional therapeutic agent is an HCV inhibitor.
7. The method of claim 6 , wherein the HCV inhibitor is an HCV protease inhibitor.
8. The method of claim 5 , wherein therapeutic agent A, therapeutic agent B, and the additional therapeutic agent are administered to the subject from the same pharmaceutical composition.
9. The method of claim 3 , wherein the pharmaceutical composition is administered to the subject once is a 24-hour period.
10. The method of claim 7 , wherein the method further comprises administering a cytochrome P-450 inhibitor.
11. The method of claim 10 , wherein the cytochrome P-450 inhibitor is ritonavir.
12. The method of claim 1 , wherein the total daily dosage of both therapeutic agent A and therapeutic agent B are administered to the subject within a twenty-four hour period.
13. The method of claim 12 , wherein the pharmaceutical composition is administered once or twice daily.